title: Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
abstract: The recent approval of liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/topiramate extended-release, brings the number of medications for long-term weight loss to 5 (including orlistat). Indicated for the treatment of patients with overweight (body mass index [BMI] ≥27 kg/m2 with ≥1 weight-related comorbidity) or obesity (BMI ≥30 kg/m2), these medications provide new opportunities to address this burgeoning health problem.
authors: Director, Nutrition and Metabolic Research Center, Center for Weight Management, Scripps Clinic, La Jolla, CA, USA.
authors: Ken
authors: K
authors: Fujioka
authors: Internal and Bariatric Medicine, Braverman-Panza Internal Medicine, Albany, NY, USA.
authors: Jill
authors: J
authors: Braverman-Panza
mesh_terms: D019440:Anti-Obesity Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001552:Benzazepines / Q000008:administration & dosage; D015992:Body Mass Index; D016642:Bupropion / Q000008:administration & dosage; D017408:Guidelines as Topic; D006801:Humans; D007783:Lactones / Q000008:administration & dosage; D008019:Life Style; D000069450:Liraglutide / Q000008:administration & dosage; D009271:Naltrexone / Q000008:administration & dosage; D009765:Obesity / Q000188:drug therapy* / Q000628:therapy; D000077403:Orlistat; D050177:Overweight / Q000188:drug therapy; D010645:Phentermine / Q000008:administration & dosage; D011320:Primary Health Care; D012307:Risk Factors; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D019440:Anti-Obesity Agents; D001552:Benzazepines; D007783:Lactones; D016642:Bupropion; D009271:Naltrexone; C506658:lorcaserin; D000069450:Liraglutide; D000077403:Orlistat; D010645:Phentermine